Nurse-Led AF Risk Factor Management Enters Randomized Testing in Hong Kong
A new randomized trial in Hong Kong is set to test whether a structured nurse-led program can do more than offer routine counseling for people living with atrial fibrillation. The study will compare a 12-week behavioral intervention plus usual care against usual care alone in adults with symptomatic AF, with the central question focused on health-related quality of life. Symptom burden, exercise capacity, self-efficacy, health behaviors, and a broad set of cardiovascular risk markers will also be tracked over five months.
The design reflects a practical gap in AF care. International guidelines now treat comorbidity and risk factor control as a core part of management, yet real-world follow-through often collapses into brief advice about diet, activity, smoking, alcohol, sleep, and medications. In AF, those behaviors are not peripheral. They influence atrial stretch, inflammation, blood pressure load, metabolic stress, and autonomic tone — all of which can shape arrhythmia persistence and symptom intensity.
Why the Intervention Centers on Behavior Change
The intervention is built around a simple premise: AF management improves when patients can act on the risks that feed the disorder. Participants in the active arm will receive a one-hour face-to-face session with a cardiac nurse in week 1, then continue with a self-management booklet, six bi-weekly follow-up calls, and weekly tailored text messages. The nurse will help each participant set realistic goals and revise them over time, which turns lifestyle counseling from a one-time lecture into a staged behavioral program.
This matters because AF symptoms often outlast the moment of diagnosis. Palpitations, fatigue, and breathlessness can erode daily function even when rhythm or rate control is in place. If the program succeeds, the clinical value may come less from any single advice item and more from the cumulative effect of repeated coaching, accountability, and self-monitoring. In chronic arrhythmia care, sustained behavior change can reduce physiological stressors that keep the atria electrically unstable.
A single 12-week intervention is unlikely to reverse every driver of AF, but it may alter the trajectory of daily symptom burden and self-management confidence.
Trial Structure, Eligibility, and Follow-Up
The study will enroll about 160 adults across three hospitals in Hong Kong, with 80 assigned to the intervention arm and 80 to usual care. It is an assessor-blinded, parallel-group randomized controlled trial. Participants must be adults with symptomatic AF, community-dwelling, in possession of a smartphone, and living with at least one relevant risk factor such as hypertension, diabetes mellitus, elevated body mass index, increased waist circumference, dyslipidemia, obstructive sleep apnea, active smoking, alcohol use above the specified threshold, or physical inactivity.
The trial is restricted to Chinese adults aged 18 years or older and targets people referred for management of symptomatic paroxysmal or persistent AF in specialist outpatient clinics. Each participant will be followed for about five months, with measurements at baseline, 12 weeks, and 20 weeks. That follow-up schedule is important because the investigators are not only looking for immediate response at the end of the program, but also whether any benefit remains visible eight weeks later after the structured contacts stop.
Outcomes Reach Beyond Symptoms Alone
The primary endpoint is health-related quality of life. Secondary outcomes include AF symptom severity, functional exercise capacity measured by distance walked in six minutes, self-efficacy, and health behaviors spanning diet, physical activity, smoking status, sleep duration, alcohol intake, and medication adherence. The trial will also examine body mass index, blood pressure, fasting lipid profile, fasting blood glucose, and the American Heart Association’s Life Essential 8 score.
That outcome mix reflects the biology of AF rather than a narrow symptom-only lens. Blood pressure, adiposity, glycemic control, and lipid burden all contribute to atrial remodeling and vascular risk. Exercise capacity can reveal whether patients are moving more and tolerating activity better, while self-efficacy may show whether the program actually changes the patient’s capacity to sustain healthier routines. In a disorder where many patients cycle between symptomatic flares and medication adjustments, these measures may capture gains that a single rhythm endpoint would miss.
The inclusion of the Life Essential 8 score also pushes the trial toward broader cardiovascular prevention. AF rarely exists in isolation. A program that improves those upstream risks could have implications for stroke prevention, heart failure risk, and overall cardiovascular health, even if rhythm itself does not change dramatically over a short follow-up window.
Sample Size and Statistical Plan Aim to Detect a Meaningful Difference
The sample size calculation was built around the primary quality-of-life outcome at 12 weeks. Investigators estimate that 64 participants per arm are needed to detect an effect size of 0.5 with 80% power at a two-sided 5% significance level, using a pooled baseline standard deviation of 18.6 points from a comparable Hong Kong AF population. That estimate corresponds to a between-group difference of 9.3 points on the primary quality-of-life instrument, which exceeds the 5-point minimal clinically important difference. Allowing for 20% attrition, the study plans to recruit 160 participants.
Analysis will follow an intention-to-treat approach after double data entry. Continuous variables will be checked for normality with the Shapiro-Wilk test, and baseline characteristics will be summarized with parametric or non-parametric methods as appropriate. Primary analyses will use generalized estimating equations to assess changes over time and between groups, with group-by-time interactions and adjustment for age, sex, AF type, AF duration, left atrial size, and left ventricular ejection fraction. Statistical significance will be defined by a two-sided p value below 0.05.
The choice of a repeated-measures framework is clinically sensible. It allows the study to track whether the intervention effect strengthens, fades, or persists across the three time points rather than relying on a single before-and-after comparison.
What This Trial Could Add to AF Care
If the nurse-led program improves quality of life and symptom burden, it would support a more systematic role for structured behavioral support in AF clinics. The mechanism would be straightforward: more contact, clearer goals, better adherence, and closer attention to modifiable risks that worsen atrial instability. If the intervention also improves blood pressure, metabolic markers, and physical activity, the case becomes stronger still, because the benefit would extend beyond patient-reported outcomes into cardiovascular prevention.
The study is not yet recruiting, so the most important unanswered questions remain tied to execution and eventual results: whether patients can sustain engagement with telephone follow-up and text messaging, whether a five-month window is long enough to detect meaningful physiological change, and whether gains in quality of life can be maintained after the structured program ends. The answers will depend on the trial’s eventual data, not on the logic of the intervention alone.